Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
Department of Microbial Biotechnology, Genetic Engineering and Biotechnology Division, National Research Centre, Dokki, Giza, Egypt.
J Virol. 2018 Jun 29;92(14). doi: 10.1128/JVI.00141-18. Print 2018 Jul 15.
Induction of persistent antibody responses by vaccination is generally thought to depend on efficient help by T follicular helper cells. Since the T helper cell response to HIV Env may not be optimal, we explored the possibility of improving the HIV Env antibody response to virus-like particle (VLP) vaccines by recruiting T helper cells induced by commonly used licensed vaccines to provide help for Env-specific B cells. B cells specific for the surface protein of a VLP can internalize the entire VLP and thus present peptides derived from the surface and core proteins on their major histocompatibility complex class II (MHC-II) molecules. This allows T helper cells specific for the core protein to provide intrastructural help for B cells recognizing the surface protein. Consistently, priming mice with an adjuvanted Gag protein vaccine enhanced the HIV Env antibody response to subsequent booster immunizations with HIV VLPs. To harness T helper cells induced by the licensed Tetanolpur vaccines, HIV VLPs that contained T helper cell epitopes of tetanus toxoid were generated. Tetanol-immunized mice raised stronger antibody responses to immunizations with VLPs containing tetanus toxoid T helper cell epitopes but not to VLPs lacking these epitopes. Depending on the priming immunization, the IgG subtype response to HIV Env after the VLP immunization could also be modified. Thus, harnessing T helper cells induced by other vaccines appears to be a promising approach to improve the HIV Env antibody response to VLP vaccines. Induction of HIV Env antibodies at sufficient levels with optimal Fc effector functions for durable protection remains a challenge. Efficient T cell help may be essential to induce such a desirable antibody response. Here, we provide proof of concept that T helper cells induced by a licensed vaccine can be harnessed to provide help for HIV Env-specific B cells and to modulate the Env-specific IgG subtype response.
接种疫苗诱导持久的抗体反应通常被认为依赖于滤泡辅助性 T 细胞(Tfh)的有效辅助。由于 HIV Env 的 T 辅助细胞反应可能并不理想,我们探索了通过募集由常用的已许可疫苗诱导的 T 辅助细胞来为 Env 特异性 B 细胞提供帮助,从而改善病毒样颗粒(VLP)疫苗对 HIV Env 抗体的应答的可能性。针对 VLP 表面蛋白的 B 细胞可以内化整个 VLP,并因此在其主要组织相容性复合体 II(MHC-II)分子上呈现源自表面和核心蛋白的肽。这允许针对核心蛋白的 T 辅助细胞为识别表面蛋白的 B 细胞提供结构内帮助。一致地,用佐剂 Gag 蛋白疫苗对小鼠进行初免增强了随后用 HIV VLP 进行加强免疫时对 HIV Env 抗体的应答。为了利用已许可的破伤风类毒素疫苗诱导的 T 辅助细胞,生成了含有破伤风类毒素 T 辅助细胞表位的 HIV VLP。破伤风类毒素免疫的小鼠对含有破伤风类毒素 T 辅助细胞表位的 VLP 免疫产生了更强的抗体应答,但对缺乏这些表位的 VLP 没有应答。根据初免免疫,VLP 免疫后的 HIV Env 抗体 IgG 亚型应答也可以被修饰。因此,利用其他疫苗诱导的 T 辅助细胞似乎是一种有前途的方法,可以提高 VLP 疫苗对 HIV Env 抗体的应答。以持久保护所需的最佳 Fc 效应功能产生足够水平的 HIV Env 抗体仍然是一个挑战。有效的 T 细胞辅助可能对于诱导这种理想的抗体应答至关重要。在这里,我们提供了概念验证,证明了由已许可疫苗诱导的 T 辅助细胞可以被利用来为 HIV Env 特异性 B 细胞提供帮助,并调节 Env 特异性 IgG 亚型应答。